EGFR and non-small cell lung carcinoma: We designed a combinatorial strategy and showed that the combination of BA and EGFR-TKIs (gefitinib and osimertinib) exerted synergistic antitumor effects on intrinsically resistant NSCLC cells both in vitro and in vivo.